TG Therapeutics (NASDAQ:TGTX) Cut to Sell at StockNews.com

StockNews.com lowered shares of TG Therapeutics (NASDAQ:TGTX) from a hold rating to a sell rating in a report issued on Sunday.

A number of other brokerages have also issued reports on TGTX. TD Cowen started coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. HC Wainwright upped their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $32.16 on Friday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market cap of $5.01 billion, a PE ratio of -321.57 and a beta of 2.25. The firm has a 50 day simple moving average of $29.96 and a 200-day simple moving average of $24.24. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter last year, the firm posted $0.73 earnings per share. The company’s revenue was down 49.4% on a year-over-year basis. On average, equities analysts expect that TG Therapeutics will post 0.17 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently added to or reduced their stakes in the company. NBC Securities Inc. lifted its holdings in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of TG Therapeutics in the second quarter worth about $35,000. Blue Trust Inc. boosted its holdings in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in TG Therapeutics during the 3rd quarter valued at approximately $53,000. Finally, Values First Advisors Inc. purchased a new stake in TG Therapeutics during the 3rd quarter worth approximately $58,000. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.